Investing.com UK on Nostr: nostr:note175aqgsaj3nncuzg0h0mgdx6p3d58gursq0q9hqfwzef9uqn56pvq47r5cu

quoting note175a…r5cu

Ivonescimab Shows Superiority in First-Line Treatment of PD-L1 Positive NSCLC
===============
#47c8c5ea ver:0.26

Ivonescimab, a novel bispecific antibody, has shown superiority in treating PD-L1 positive NSCLC, outperforming pembrolizumab in a Phase III trial. It combines PD-1 blockade with anti-angiogenesis effects, making it a promising option for solid tumors. Incyte has entered a collaboration for the development of povorcitinib, a drug targeting JAK1 enzymes. Cybin is developing psychedelic treatments for mental health conditions, while Owkin unveils its precision AI drug pipeline in oncology and immunology. DelveInsight's report provides insights into the Parkinson's Disease pipeline landscape, including promising drugs and key companies. #cancer #precisionmedicine #mentalhealth #ParkinsonsDisease...

#newstr #Ivonescimab #Pdl1PositiveNsclc #Nsclc #CancerTreatment #Collaboration #PipelineUpdates #Parkinson'sDisease

https://here.news/story/47c8c5ea?ver=0.26